The Latest Breaking News from BMY

Cooling inflationary pressures, a slowdown in the Fed’s interest rate hikes, and easing recession fears are contributing to improved investor sentiment lately. Amid growing investor optimism, fundamentally sound stocks Bristol-Myers Squibb (BMY) and General Motors (GM) could be wise additions to your portfolio to start 2023 right. Continue reading….

The pharmaceutical industry is well-positioned for significant growth in the near future, given the growing demand for medicines and increasing R&D activities. Given the industry's inelastic demand, fundamentally strong pharma stocks AstraZeneca (AZN), Bristol-Myers Squibb (BMY), and GSK plc (GSK) might be solid long-term investments. Continue reading….

Bristol's Revlimid took fewer than expected generic hits in the fourth quarter, resulting in a beat and a pop for BMY stock Thursday.

Consistently falling prices and stronger-than-expected fourth-quarter GDP are renewing hopes about the economy’s overall health. Therefore, it could be wise to add quality stocks with solid fundamentals, Walmart (WMT), Bristol-Myers Squibb (BMY), and CVS Health (CVS), to your portfolio to garner substantial returns in 10 years. Read more….

The Fed’s indication to keep raising interest rates through this year and looming recession fears will likely keep the stock market under pressure for the near term. Therefore, investors looking for stability amid an uncertain macroeconomic environment could consider buying fundamentally strong dividend-paying healthcare stocks Johnson & Johnson (JNJ), Pfizer…

The incessant rate hikes have led to significant market volatility and raised recessionary fears. However, with inflation finally cooling and wage growth slowing down, we think fundamentally strong stocks Bristol-Myers Squibb (BMY), Cardinal Health (CAH), and KT Corp (KT), which are rated A (Strong Buy) in our proprietary rating system,…

Inflation eased for the second consecutive month in November, and the Fed slowed down the pace of rate hikes after four straight 75-basis-point hikes. However, recession fears loom as the central bank plans to raise rates through next year. Regardless of the economic uncertainties, it could be wise to invest…

Despite macroeconomic challenges, leading pharma company Bristol-Myers Squibb (BMY) has the robustness and resilience to deliver value for shareholders. Read on….

Despite rampant market volatility, Goldman Sachs expects the U.S. economy to avoid a recession. However, as uncertainties remain, medical stocks Pfizer (PFE) and Bristol-Myers Squibb (BMY), which pay reliable dividends, could be ideal buys to ensure a steady income stream. Keep reading….

Amid rising global medical needs, the pharmaceutical industry is expected to witness robust growth in the coming years. Moreover, healthcare is considered relatively resilient amid market downturns. So, given the economic uncertainties, investors could consider buying quality pharmaceutical stocks such as Pfizer (PFE), Novartis (NVS), and Bristol-Myers Squibb (BMY) this…

While the moderate inflation rate for November has boosted investor sentiment and may have paved the way for lower interest rate hikes from this month, Fed’s recent comments suggest that the target interest rate may be a bit further ahead. Hence shares of fundamentally strong businesses with robust demand, such…